PNC Financial Services Group Inc. trimmed its stake in Humana Inc. (NYSE:HUM - Free Report) by 3.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,194 shares of the insurance provider's stock after selling 3,272 shares during the period. PNC Financial Services Group Inc. owned 0.07% of Humana worth $25,717,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Bessemer Group Inc. raised its stake in shares of Humana by 143.4% in the first quarter. Bessemer Group Inc. now owns 6,436 shares of the insurance provider's stock worth $2,230,000 after buying an additional 3,792 shares during the period. Advisors Asset Management Inc. boosted its position in shares of Humana by 4.5% in the first quarter. Advisors Asset Management Inc. now owns 5,370 shares of the insurance provider's stock worth $1,862,000 after purchasing an additional 230 shares during the period. Lazard Asset Management LLC increased its stake in shares of Humana by 8.2% in the first quarter. Lazard Asset Management LLC now owns 406,993 shares of the insurance provider's stock worth $141,110,000 after purchasing an additional 30,778 shares in the last quarter. Bellevue Group AG raised its position in shares of Humana by 34.9% during the 1st quarter. Bellevue Group AG now owns 135,541 shares of the insurance provider's stock valued at $46,995,000 after purchasing an additional 35,069 shares during the period. Finally, Ceeto Capital Group LLC lifted its stake in shares of Humana by 30.6% during the 1st quarter. Ceeto Capital Group LLC now owns 2,560 shares of the insurance provider's stock valued at $890,000 after buying an additional 600 shares in the last quarter. 92.38% of the stock is owned by institutional investors.
Shares of HUM stock opened at $296.39 on Friday. The company has a market capitalization of $35.69 billion, a P/E ratio of 26.25, a P/E/G ratio of 2.19 and a beta of 0.52. The company's 50-day simple moving average is $277.30 and its two-hundred day simple moving average is $330.79. Humana Inc. has a one year low of $213.31 and a one year high of $527.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analysts' expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities analysts anticipate that Humana Inc. will post 15.86 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana's payout ratio is 31.36%.
HUM has been the subject of a number of analyst reports. Stephens reiterated an "equal weight" rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Leerink Partners downgraded Humana from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. UBS Group dropped their price target on Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a research note on Friday, October 4th. Piper Sandler cut shares of Humana from an "overweight" rating to a "neutral" rating and cut their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Finally, Sanford C. Bernstein upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $308.00 price target on the stock in a research note on Tuesday, October 8th. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $315.86.
Check Out Our Latest Stock Analysis on Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.